Â鶹ӳ»­

Phase I Clinical Trials Program

The Department of Investigational Cancer Therapeutics conducts broad Phase I studies across disease boundaries and molecular targets. We strive to provide outstanding patient care while performing innovative Phase I trials with new drugs that may eventually improve the management of cancer.

Under the leadership of Department Chair Dr. Funda Meric-Bernstam, Deputy Department Chair Dr. David Hong and Department Administrator Yagut Retondo, our program has become a centralized resource for patients, physicians and scientists who are looking for new experimental Phase I therapies that may eventually represent advances in cancer research and treatment.

Goals 

• To provide novel cancer treatment options to patients with cancer
• To improve treatment options for patients with cancer through research and discovery
• To provide education, instruction, and training for the next generation of clinical researchers through fellowship and publications

You also can learn about the Clinical Center for Targeted Therapy, which is dedicated to providing excellent care to our patients by bringing the newest agents for cancer treatment more quickly from the laboratory to clinical trials.

Areas of Expertise

Our department is at the forefront of cancer research, with expertise spanning key areas of translational oncology. We specialize in targeting KRAS-driven cancers, advancing antibody-drug conjugates (ADCs) and developing innovative strategies in DNA damage response (DDR). Our team also explores novel immuno-oncology (IO) approaches, cellular therapies, intratumoral injections and precision-targeted therapies ¡ª all aimed at enhancing treatment efficacy and improving patient outcomes.